S0947000
Somatropin
European Pharmacopoeia (EP) Reference Standard
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
Productos recomendados
grado
pharmaceutical primary standard
familia API
somatropin
fabricante / nombre comercial
EDQM
aplicaciones
pharmaceutical (small molecule)
formato
neat
temp. de almacenamiento
−20°C
¿Está buscando productos similares? Visita Guía de comparación de productos
Descripción general
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Aplicación
Somatropin EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Envase
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Otras notas
Sales restrictions may apply.
Producto relacionado
Referencia del producto
Descripción
Precios
Código de clase de almacenamiento
11 - Combustible Solids
Clase de riesgo para el agua (WGK)
WGK 3
Punto de inflamabilidad (°F)
Not applicable
Punto de inflamabilidad (°C)
Not applicable
Elija entre una de las versiones más recientes:
Certificados de análisis (COA)
Lot/Batch Number
Lo sentimos, en este momento no disponemos de COAs para este producto en línea.
Si necesita más asistencia, póngase en contacto con Atención al cliente
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
E Elowe-Gruau et al.
Revue medicale suisse, 10(418), 424-424 (2014-03-20)
Children born premature and/or small for gestational age (SGA) are at risk of growth and metabolic abnormalities. Catch-up growth occurs usually before the age of 2. In the absence of sufficient catch up growth, growth hormone (GH) treatment should be
Małgorzata Partyka et al.
Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 36(211), 63-67 (2014-03-22)
Growth hormone (GH) is a polypeptide hormone produced by the cells of pituitary. Production of growth hormone is carried out in a pulsating manner, and the frequency and intensity of the pulses is dependent on age and gender. Growth hormone
A Thankamony et al.
The Journal of clinical endocrinology and metabolism, 99(2), 639-647 (2014-01-16)
Data on the metabolic effects of GH derived from studies using GH suppression by pharmacological agents may not reflect selective actions. The purpose of this study was to evaluate the effects of GH antagonism on glucose and lipid metabolism using
Mark Sherlock et al.
The Journal of clinical endocrinology and metabolism, 99(2), 478-485 (2013-11-19)
Acromegaly is associated with reduced life expectancy, which has been reported to be normalized if treatment is successful in controlling GH/IGF-I levels. Most previous studies have invariably used the last available GH/IGF-I, which may be biased as it only assesses
J R Delanghe et al.
Acta clinica Belgica, 69(1), 25-29 (2014-03-19)
The recent Armstrong case, where more than 250 negative doping tests are confronted with the athlete's confession of erythropoietin use, blood doping, steroid, and growth hormone abuse, illustrates the limitations of current laboratory tests in detecting doping in sport. Despite
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico